| Long-term benefit of interferon α therapy of chronic hepatitis D: regression of advanced hepatic fibrosis P Farci, T Roskams, L Chessa, G Peddis, AP Mazzoleni, R Scioscia, ... Gastroenterology 126 (7), 1740-1749, 2004 | 373 | 2004 |
| Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome P Farci, R Strazzera, HJ Alter, S Farci, D Degioannis, A Coiana, G Peddis, ... Proceedings of the National Academy of Sciences 99 (5), 3081-3086, 2002 | 270 | 2002 |
| Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B P Lampertico, M Viganò, GG Di Costanzo, E Sagnelli, M Fasano, ... Gut 62 (2), 290-298, 2013 | 154 | 2013 |
| Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy MG Carta, MC Hardoy, A Garofalo, E Pisano, V Nonnoi, G Intilla, G Serra, ... Clinical Practice and Epidemiology in Mental Health 3, 1-4, 2007 | 135 | 2007 |
| Human leukocyte antigen complex and other immunogenetic and clinical factors influence susceptibility or protection to SARS-CoV-2 infection and severity of the disease course … R Littera, M Campagna, S Deidda, G Angioni, S Cipri, M Melis, D Firinu, ... Frontiers in immunology 11, 605688, 2020 | 116 | 2020 |
| Association of chronic hepatitis C with recurrent brief depression MG Carta, J Angst, MF Moro, G Mura, MC Hardoy, C Balestrieri, L Chessa, ... Journal of affective disorders 141 (2-3), 361-366, 2012 | 54 | 2012 |
| Treatment of chronic hepatitis D P Farci, L Chessa, C Balestrieri, G Serra, ME Lai Journal of viral hepatitis 14, 58-63, 2007 | 54 | 2007 |
| Real-world experience with obeticholic acid in patients with primary biliary cholangitis D D’Amato, A De Vincentis, F Malinverno, M Viganò, D Alvaro, M Pompili, ... JHEP Reports 3 (2), 100248, 2021 | 53 | 2021 |
| Modeling cost‐effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real‐life cohort LA Kondili, F Romano, FR Rolli, M Ruggeri, S Rosato, MR Brunetto, ... Hepatology 66 (6), 1814-1825, 2017 | 49 | 2017 |
| Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network LA Kondili, GB Gaeta, MR Brunetto, A Di Leo, A Iannone, TA Santantonio, ... PLoS One 12 (10), e0185728, 2017 | 46 | 2017 |
| Forecasting Hepatitis C liver disease burden on real‐life data. Does the hidden iceberg matter to reach the elimination goals? LA Kondili, S Robbins, S Blach, I Gamkrelidze, AL Zignego, MR Brunetto, ... Liver International 38 (12), 2190-2198, 2018 | 45 | 2018 |
| Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV A Karampatou, X Han, LA Kondili, G Taliani, A Ciancio, F Morisco, ... Journal of Hepatology 68 (1), 33-41, 2018 | 42 | 2018 |
| Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection R Littera, L Chessa, S Deidda, G Angioni, M Campagna, S Lai, M Melis, ... PloS One 16 (8), e0255608, 2021 | 41 | 2021 |
| Gastrointestinal coronavirus disease 2019: epidemiology, clinical features, pathogenesis, prevention, and management S Deidda, L Tora, D Firinu, S Del Giacco, M Campagna, F Meloni, G Orru, ... Expert Review of Gastroenterology & Hepatology 15 (1), 41-50, 2021 | 38 | 2021 |
| Exploring the role of killer cell immunoglobulin-like receptors and their HLA class I ligands in autoimmune hepatitis R Littera, L Chessa, S Onali, F Figorilli, S Lai, L Secci, G La Nasa, ... PLoS One 11 (1), e0146086, 2016 | 30 | 2016 |
| Add‐on peginterferon alfa‐2a to nucleos (t) ide analogue therapy for Caucasian patients with hepatitis B ‘e’antigen‐negative chronic hepatitis B genotype D P Lampertico, MR Brunetto, A Craxì, GB Gaeta, M Rizzetto, A Rozzi, ... Journal of Viral Hepatitis 26 (1), 118-125, 2019 | 28 | 2019 |
| Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin C Cauli, G Serra, L Chessa, C Balestrieri, R Scioscia, ME Lai, P Farci Haematologica 91 (6_Suppl), ECR26-ECR26, 2006 | 27 | 2006 |
| Interferon-alpha-induced psychiatric side effects in patients with chronic viral hepatitis: a prospective, observational, controlled study MG Orrù, A Baita, R Sitzia, A Costa, E Muntoni, S Landau, L Chessa, ... Epidemiology and Psychiatric Sciences 14 (3), 145-153, 2005 | 26 | 2005 |
| Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a … S Petta, M Marzioni, P Russo, A Aghemo, A Alberti, A Ascione, A Antinori, ... The Lancet Gastroenterology & Hepatology 2 (6), 427-434, 2017 | 23 | 2017 |
| Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver. AP Gramenzi A, Conti F, Cammà C, Grieco A, Picciotto, AHES Group. Digestive and Liver Disease 44 (8), 674-680, 2012 | 22 | 2012 |
